Plus Therapeutics, Inc. announced on August 18, 2025, positive data from the ReSPECT-LM Phase 1 single dose escalation trial. The results were presented at the SNO/ASCO CNS Metastases Conference in Baltimore, MD.
The data demonstrated that treatment of leptomeningeal metastases (LM) with REYOBIQ is feasible, has a manageable safety profile, and shows a promising efficacy signal. REYOBIQ produced a clinical benefit rate of over 75% across three clinically relevant outcome measures.
Results from 29 subjects in cohorts 1-6 showed that RNA sequencing and circulating tumor cell reduction were consistent with tumor cell death. No dose-limiting toxicities were observed, indicating an overall favorable safety profile for the treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.